Form 4: Blueprint Medicines COO Christina Rossi Sells Shares Under 10b5-1 Trading Plan

Christina Rossi, Chief Operating Officer of Blueprint Medicines Corp, sold shares of common stock on December 18, 2024, under a pre-arranged trading plan.

Summary

• Christina Rossi, the Chief Operating Officer of Blueprint Medicines Corp, reported the sale of company stock on December 18, 2024.
• The sales were executed under a pre-arranged trading plan adopted on August 27, 2024, in accordance with Rule 10b5-1.
• A total of 2,274 shares of common stock were sold in two separate transactions.
• The first transaction involved the sale of 2,166 shares at an average price of $95.88.
• The second transaction involved the sale of 108 shares at a price of $96.5.
• Following these transactions, Rossi directly owns 69,383 shares of Blueprint Medicines Corp.
• The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the range set forth in the footnote.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative news about the company's performance.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• While the sales are under a 10b5-1 plan, large insider sales can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. The market reaction to this news will depend on various factors, including the overall market sentiment and the company's performance.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate executives to sell shares without raising concerns about insider trading, similar to practices seen at companies like Amgen or Regeneron.
• The volume of shares sold is relatively small compared to the total outstanding shares of Blueprint Medicines, which is typical for routine insider sales.

Stakeholder Impact

• The impact on shareholders is likely to be minimal, as the sales were conducted under a pre-arranged trading plan and represent a small percentage of the outstanding shares.

Key Dates